Re-Stem Biotech Research Collaboration Featured on Johns Hopkins Technology Ventures' Website

SUZHOU, China - Sept. 19, 2019 - PRLog -- Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, has recently been featured on Johns Hopkins Technology Ventures' website regarding Re-Stem's sponsored research agreement with Johns Hopkins University (JHU), on behalf of its School of Medicine. The collaboration aims to conduct an academic research study titled "Molecular Pathways that Modulate the Mitochondria-Proteostasis Relationship during the Progression of Parkinson's Disease and related neurodegenerative diseases".

"We are very pleased to partner with such a highly respected institution as Johns Hopkins University in our efforts to address degenerative conditions," CEO Benno Jiao is quoted as saying in the story.

Read the full story here:

About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, Kunming and Ganzhou.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as "will," "may," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.

Media Contact
Judyanna Chen
Re-Stem Biotech
Email:*** Email Verified
Tags:Johns Hopkins, ReStem, Venture
Location:suzhou - Jiangsu - China
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share